Plain-English translation of NCT07071623 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing a new HIV prevention medication called , taken once a month, to see if it works better than the current standard prevention pill that you take every day. Researchers want to understand both how well this medication prevents HIV infection and whether it is safe and well-tolerated by women. The study will compare the new monthly treatment against the established daily prevention approach.
Currently, the most common HIV prevention pill requires taking medication every single day, which can be challenging for many people. This trial exists to see if a medication you only have to take once a month could be more practical and effective, making HIV prevention easier and more accessible for women.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would be randomly assigned to receive either the new monthly medication plus a daily placebo (inactive pill), or the standard daily prevention pill plus a monthly placebo injection. You would continue this for about 2 years, with regular clinic visits for health checks, testing, and support. After the main study ends, you would receive the standard prevention medication for an additional 28 days to ensure you remain protected.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
Kenya
South Africa